Novocure Ltd. is a global oncology company developing Tumor Treating Fields (TTFields)—a non-invasive therapy that uses electric fields to disrupt cancer cell division. Its wearable devices, like Optune, are approved for treating glioblastoma and mesothelioma.
Novocure is expanding its clinical pipeline to include other solid tumors such as pancreatic and lung cancers. As of May 29, 2025, its stock (NASDAQ: NVCR) trades at $19.40.
| Company | Catalyst | Successful? | Gain/Loss (%) | Chart | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NVCR | Double Bottom | Jan. 9, 2019 | Bullish |
✅
|
+45.0% | Detail https://breakoutdb.com/nvcr/nvcr-double-bottom-2019-01-09/ | |||
| 2 | NVCR | Double Bottom | Jan. 8, 2019 | Choppy |
❌
|
2.2% | Detail https://breakoutdb.com/nvcr/nvcr-double-bottom-2019-01-08/ |
(*) This trade is still active; the gain is an estimate based on the current price.
